India, Nov. 17 -- Erasca, Inc. (ERAS) announced a clinical trial collaboration with Bristol Myers Squibb (BMY) to evaluate ERAS-0015, Erasca's investigational pan-RAS molecular glue, in combination with navlimetostat, Bristol Myers Squibb's investigational PRMT5 inhibitor, for patients with a form of pancreatic cancer characterized by MTAP deletion.
Pancreatic cancer remains one of the most difficult cancers to treat, and many tumors carry mutations in the RAS signaling pathway that drive cancer growth.
Under the agreement, the combination will be studied in a Phase 1/2 clinical trial involving patients with MTAP-deleted pancreatic ductal adenocarcinoma (PDAC). Bristol Myers Squibb will sponsor the study, while Erasca will supply ERAS-001...